Syndax Pharmaceuticals ( SNDX ), a developer of cancer therapies, Thursday reported its phase 1b/2 trial of entinostat in combination with pembrolizumab, a Merck ( MRK ) drug, continues "to support the potential for the entinostat-pembrolizumab combination" to treat certain types of lung, skin and colorectal cancers.
Syndax reported, "Confirmed objective responses with the combination regimen have been observed across all cohorts. Updated data continue to demonstrate a manageable toxicity profile for the entinostat-pembrolizumab combination, with treatment emergent adverse events observed consistent with those previously reported."
Syndax said trial data will be presented at the American Society of Clinical Oncology annual meeting being held June 1-5 in Chicago.
The company slated an 8:30 am ET conference call.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.